Table 3.
Adjusteda 400-m walking speed and SPPB score at each follow-up time, by metabolic syndrome (MetS) status and intervention group.
Non-MetS | MetS | |||||
---|---|---|---|---|---|---|
|
|
|
|
|||
PA | HE | PA | HE | |||
|
|
|
|
|
|
|
Mean (SE) | Mean (SE) | P-value (for difference PA-HE) | Mean (SE) | Mean (SE) | P-value (for difference PA-HE) | |
400-m walking speed (m/s)baseline | 0.84 (0.01) | 0.84 (0.01) | 0.96 | 0.81 (0.01) | 0.80 (0.01) | 0.15 |
6 months | 0.85 (0.01) | 0.83 (0.01) | 0.03 | 0.85 (0.01) | 0.81 (0.01) | <0.001 |
12 months | 0.82 (0.01) | 0.81 (0.01) | 0.53 | 0.82 (0.01) | 0.79 (0.01) | <0.001 |
18 months | 0.81 (0.01) | 0.80 (0.01) | 0.42 | 0.81 (0.01) | 0.77 (0.01) | <0.001 |
24 months | 0.79 (0.01) | 0.78 (0.01) | 0.64 | 0.79 (0.01) | 0.75 (0.01) | <0.001 |
30 months | 0.75 (0.01) | 0.76 (0.01) | 0.50 | 0.77 (0.01) | 0.74 (0.01) | 0.03 |
36 months | 0.74 (0.01) | 0.75 (0.01) | 0.41 | 0.75 (0.01) | 0.73 (0.01) | 0.24 |
42 months | 0.73 (0.02) | 0.76 (0.02) | 0.30 | 0.74 (0.02) | 0.68 (0.01) | 0.01 |
Overall effectb | 0.91 | <0.001 | ||||
P-value for interactionc = 0.07 | ||||||
SPPB scored baseline | 7.37 (0.08) | 7.44 (0.08) | 0.55 | 7.45 (0.08) | 7.23 (0.08) | 0.06 |
6 months | 8.50 (0.11) | 8.21 (0.11) | 0.06 | 8.46 (0.11) | 8.10 (0.11) | 0.02 |
12 months | 8.20 (0.11) | 8.06 (0.11) | 0.33 | 8.46 (0.11) | 8.05 (0.11) | 0.01 |
24 months | 7.92 (0.11) | 7.78 (0.11) | 0.34 | 7.96 (0.11) | 7.75 (0.11) | 0.18 |
36 months | 7.75 (0.15) | 7.48 (0.15) | 0.21 | 7.68 (0.15) | 7.70 (0.15) | 0.92 |
Overall effectb | 0.11 | 0.07 | ||||
P-value for interactionc = 0.22 |
Abbreviations: MetS – metabolic syndrome; PA – physical activity; HE – health education; SPPB – Short Physical Performance Battery.
Adjusted for clinical site and gender.
Overall difference in 400-m walk speed and SPPB across follow-up time points, adjusted for baseline value.
Interaction terms included MetS * intervention group, MetS * time, intervention group * time, and MetS * group * time terms.
Per inclusion criteria, participants were eligible if they had a baseline SPPB score of 9 or less; SPPB scores could potentially be >9 at follow-up visits.